⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ARQT News
Arcutis Biotherapeutics, Inc. Common Stock
Arcutis Management to Present at TD Cowen’s 46th Annual Health Care Conference
globenewswire.com
ARQT
Form 8-K
sec.gov
ARQT
Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
globenewswire.com
ARQT
Professional Golfer Max Homa Joins Arcutis’ Free to Be Me Campaign, Urging Individuals with Seborrheic Dermatitis to Tee Up a Conversation with Their Healthcare Provider About Long-Term Treatments
globenewswire.com
ARQT
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
ARQT
Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis
globenewswire.com
ARQT
Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa
globenewswire.com
ARQT
Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference
globenewswire.com
ARQT
Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions
globenewswire.com
ARQT
Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones
globenewswire.com
ARQT